Contrast-enhanced ultrasound for sentinel node detection in patients with melanoma, breast cancer or head & neck cancer (N24CUS)

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515259-40-00

Enrollment

Registered

2024-12-09

Start date

2025-07-07

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer, melanoma, head & neck cancer

Brief summary

sensitivity and specificity of the CEUS SN localization method

Detailed description

time required to localize the SNs using CEUS in minutes, usability of the CEUS system using a system-usability-score (SUS), sensitivity and specificity of using CEUS to predict if SNs are malignant

Interventions

DRUGSonazoid 8 mikroliter per ml pulver og væske til injeksjonsvæske

DRUGdispersjon

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
sensitivity and specificity of the CEUS SN localization method	—

Secondary

Measure	Time frame
time required to localize the SNs using CEUS in minutes, usability of the CEUS system using a system-usability-score (SUS), sensitivity and specificity of using CEUS to predict if SNs are malignant	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026